Publication
First-line management of unresectable hepatocellular carcinoma: clinical perspectives from the CheckMate 9DW study.
Bruno Sangro, Peter Galle, David Tai, Thomas Yau
Future oncology (London, England)Sep 22, 2026PMID 42770869doi:10.1080/14796694.2026.2726118 Journal ArticlepubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 29, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260929-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
In this podcast, over a series of four parts, the authors provide an overview of the CheckMate 9DW study (NCT04039607) in hepatocellular carcinoma (HCC) and their opinions on how it impacts the treatment landscape for first-line unresectable HCC. The first two parts provide an overview of the…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 1
- trialNCT04039607registry_reference1.00
Registered trialsNCT04039607
Curated evidence
Evidence citing this paper (0)
Data not yet available
No curated evidence item cites this publication.